Home › Funds › Vestal Point Capital, LP › TRVI

Vestal Point Capital, LP position in TRVI

TREVI THERAPEUTICS INC · Health Care

Vestal Point Capital, LP reported holding 3,100,000 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$57.8M, representing 1.35% of its reported portfolio and ranking #25 among its reported holdings. Vestal Point Capital, LP has disclosed TRVI holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)3.10M sh
Reported value held$57.81M
Portfolio Weight1.35%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's TRVI position evolved

Vestal Point Capital, LP first disclosed a stake in TRVI in Q1 2026 at 2,166,504 shares (US$25.8M). The position peaked in Q2 2026 at 3,100,000 shares, worth US$57.8M. Across 2 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,100,000 shares valued at US$57.8M — an increase of 933,496 shares quarter over quarter.. Notable position changes include a 43% increase in Q2 2026 (shares fell 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 2.17M $25.85M New
Q2 2026 3.10M $57.81M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has Vestal Point Capital, LP held TRVI?

Vestal Point Capital, LP has disclosed TRVI holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Vestal Point Capital, LP's current position in TRVI?

As of Q2 2026, Vestal Point Capital, LP holds 3.10M shares of TRVI (TREVI THERAPEUTICS INC), valued at $57.81M, representing 1.35% of its reported portfolio and ranking #25.

Has Vestal Point Capital, LP been buying or selling TRVI?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in TRVI. The position peaked in Q2 2026 at 3.10M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.